Category Specific RSS

myelofibrosis

FDA gives green light to Pharmaxis drug trial in liver cancer where there’s a desperate need for new treatments

Clinical stage drug development company, Pharmaxis (ASX: PXS) is making a name for themselves in the oncology sector, with their…

4 years ago

First cohort responds well to Pharmaxis cancer treatment drug – next phase of clinical trial fully subscribed

Promising early study results released today by clinical stage drug development company Pharmaxis (ASX: PXS), should be a reason for…

4 years ago

Pharmaxis streamlines operations with $2m sale of Russian distribution rights

Streamlining operations to focus on the most profitable side of their pharmaceuticals manufacturing business, Pharmaxis (ASX: PXS) has shored up…

5 years ago

Pharmaxis shares present untapped value as the drug developer pursues a rare cancer therapy

In biotech circles, tackling a rare and difficult disease with few patients does not necessarily equate to targeting an unprofitable…

5 years ago

Pharmaxis targeting scar-free recovery from burns with world-first trials

One of the world’s most respected surgeons in the field of burns and trauma recovery will lead world-first clinical trials…

5 years ago